From fully bespoke cell engineering to rapid standardised expression cell lines and ready-to-use cell products, RoukenBio can align with your timeline, complexity, and scientific goals. Whether you need premium custom cell engineering, a rapid overexpression cell line with your target antigen, or an off-the-shelf product, our cell engineering offering is designed to help you get to the right answer.
Not every project needs the same level of cell engineering. Some programmes require a bespoke, scientist-led approach with custom design, expanded QC and functional validation. Others need a faster, lower-complexity route for straightforward overexpression work. In some cases, we may already have a ready-to-use cell product that fits directly into your assay workflow.
Choose the route that best matches your project complexity, timeline and intended application.
Premium Cell Engineering Service
Custom Cell Line Express Service
RoukenCells Pre-Developed Cell Products
Bespoke scientist-led cell engineering for complex or non-standard drug development projects.
For complex, high-specification, or non-standard projects, our Premium Cell Engineering Service provides a scientist-led bespoke route tailored around your exact research needs. This is the right choice when your project requires complex design and technical consultation.
Start a Premium Cell Engineering RequestBespoke scientist-led cell engineering for complex or non-standard drug development projects.
For complex, high-specification, or non-standard projects, our Premium Cell Engineering Service provides a scientist-led bespoke route tailored around your exact research needs. This is the right choice when your project requires complex design and technical consultation.
A faster standardised route for simple target overexpression projects.
Our Custom Cell Line Express Service is designed for therapeutic developers who need a rapid, cost-effective route to simple overexpression cell lines without the complexity of a fully bespoke engineering programme.
Using RoukenBio’s proprietary targeted integration LocIn platform cell lines, this service supports standardised generation of target-expressing cell lines in CHO-K1 or HEK293 backgrounds.
It is designed to answer straightforward or proof-of-concept questions efficiently. The Cell Line Express service offers a fast, cost-effective route to cell line generation, particularly for projects requiring overexpression of one or two targets.
Ready-to-use cell products that plug straight into your functional in-house assays.
RoukenCells gives you access to pre-developed, assay-ready cell products designed to help therapeutic developers move faster and integrate reliable cellular tools directly into their assay workflows.
Available RoukenCells product categories:
Tell us what you need and we will help route you to the right solution for your therapeutic development project.
Talk to a Cell Engineering Specialist
RoukenBio combines extensive cell engineering experience with deep immunology, molecular biology and assay development expertise. We build engineered cell lines with the end application in mind, helping customers generate stable, reproducible and biologically relevant systems for therapeutic discovery and development.
From rapid overexpression projects to bespoke inducible, reporter, gene-edited assay-ready cell lines, our scientists help define the most appropriate engineering route based on your biological question, project complexity and downstream workflow.
Our tiered service model gives you flexible access to the right level of support; from off-the-shelf RoukenCells products to rapid Custom Cell Line Express projects, through to premium bespoke cell engineering programmes requiring scientific design, expanded QC and functional validation.
Our scientists combine deep immunology expertise with advanced molecular biology techniques to produce engineered cell lines that are stable, reproducible, and precisely tailored to your therapeutic modality. Every cell line engineering service we offer follows a collaborative, problem-solving approach, ensuring we build the right cellular system to answer the right biological question.
Inducible Expression with IndEx-2
LocIn – Targeted integration system
Gene Editing
Reporter Cell Lines
Target-Expressing Cell Lines
Defined Expression Levels
CAR-T Cells
The IndEx-2 system evaluates antigen density and activation thresholds to address on-target, off-tumour side effects in antibody-targeted therapies. This system controls the expression of one or two proteins over a dynamic range, linking antigen density to activation thresholds for cytolysis and cytokine release. This innovative approach supports screening, characterisation, and lead selection for mono- and dual-targeted therapies.
Titratable expression of one or two antigens with a large dynamic range.
The utility of the system is characterised by three key attributes:
The IndEx-2 assays system is a robust in vitro model to evaluate the influence of antigen expression levels on a targeted therapeutic’s efficacy and safety. This versatile tool enables the controlled expression of one or two antigens of interest, and uniquely allows for the estimation of antigen expression thresholds required for therapeutic activation.
SEE OUR WEBINARThe IndEx-2 system evaluates antigen density and activation thresholds to address on-target, off-tumour side effects in antibody-targeted therapies. This system controls the expression of one or two proteins over a dynamic range, linking antigen density to activation thresholds for cytolysis and cytokine release. This innovative approach supports screening, characterisation, and lead selection for mono- and dual-targeted therapies.
Titratable expression of one or two antigens with a large dynamic range.
The utility of the system is characterised by three key attributes:
The IndEx-2 assays system is a robust in vitro model to evaluate the influence of antigen expression levels on a targeted therapeutic’s efficacy and safety. This versatile tool enables the controlled expression of one or two antigens of interest, and uniquely allows for the estimation of antigen expression thresholds required for therapeutic activation.
LocIn is an advanced targeted integration system that allows the efficient generation of genetically identical isogenic mammalian cell lines. LocIn’s unique targeted integration and selection systems remove the need for the subcloning and analysis of clones, reducing both the time and effort required for cell line generation, without compromising quality.
The LocIn system allows for the accurate comparisons of construct designs, through the standardisation of integration patterns. By eliminating positional and context-dependent effects, LocIn enables accurate studies of phenotypic outcomes, delivering reliable genotype-to-phenotype correlations. This makes the system well suited for use in the generation of cell lines for toxicology species cross-reactivity assessments, as expression variability resulting from integration pattern differences across expression constructs is normalised.
LocIn offers both single and multi-platform systems to meet your cell line engineering needs, whether you require low or high expression.
With LocIn, you have precise control, minimising integration artefacts and ensuring consistency across experiments.
LocIn is an advanced targeted integration system designed for the efficient generation of cell lines by retargeting pre-defined genomic loci, known as "landing pads." These landing pads incorporate a fluorescent protein marker, enabling the easy identification of integrations at genomic sites that support high transgene expression.
The system leverages Recombinase Mediated Cassette Exchange (RMCE) to precisely replace the landing pad cassette with a gene of interest. This approach ensures the complete removal of the original cassette during retargeting while exclusively integrating the desired gene. The two step selection process ensures that in the multiplatform system, all platforms are retargeted in the final clonal pool.
Join Timothy London, Director of Molecular Biology & Cell Engineering and one of the key developers behind the advanced LocIn system, as he unveils it in our webinar.
We utilise the royalty-free nuclease, enabling us to generate bespoke knockout or knock in cell lines for our customers. Such gene edited cell lines can be combined with our other technologies, such as the inducible IndEx-2 system, allowing the creation of cell line in a relevant background with inducible expression of the target antigen of interest.
RoukenBio offers custom reporter cell lines to fit the needs of your specific assays, including bioluminescent and fluorescent reporter cell lines, checkpoint blockade reporters (such as PD-1/PD-L1 blockade) as well as fully artificial reporter systems that can be used to monitor the activation of receptor tyrosine kinases or G protein coupled receptors (GPCRs). We have a diverse range of ready to go reporter cell lines, ready to be utilised in assays in-house at RoukenBio, or be shipped to your facility for use in your own assays.
Reporter system engineered into HEK293 generated HEK STAT6 RE cells shows a dose-dependent IL-13 response.
Our in-house expertise in the design and generation of bespoke target expressing recombinant cell lines provides you with the best possible cell line for your specific needs. We also have an ever-growing collection of pre-developed target-expressing cell lines engineered to express specific targets of interest for drug screening and validation studies.
Engineered target cells were opsonised with an antibody drug molecule and incubated with cryopreserved PBMCs to determine ADCC activity as compared to a reference standard.
We have expertise in the utilisation of expression attenuation techniques to create recombinant stable cell lines with defined levels of expression of your target antigen(s). These cells lines can be used in vitro for modelling the expression levels of tumour associated target antigens found in both healthy and diseased tissues and used in in vivo mouse models, for investigating the effect of tumour cell target antigen density on the efficacy and safety profile of a therapeutic.
Our cell line development experts have experience and expertise in the design of 1st to 4th generation chimeric antigen receptors (CARs). We have predeveloped protocols for the generation and expansion of CAR expressing primary αβ and γδ T cells. We also have in-house developed Jurkat NFAT luciferase reporter cell lines that can be used as a background for CAR expression. These primary or Jurkat CAR-T cells can be utilised as effector cells in our suite of functional assays.
Discover the latest dual inducible IndEx-2 data and dive into two in-depth CAR-T case studies in our exclusive technical slide deck.
